Treatment of pediatric acute lymphoblastic leukemia (ALL) is based on the concept of tailoring the intensity of therapy to a patient's risk of relapse. To determine whether gene expression profiling could enhance risk assignment, we used oligonucleotide microarrays to analyze the pattern of genes expressed in leukemic blasts from 360 pediatric ALL patients. Distinct expression profiles identified each of the prognostically important leukemia subtypes, including T-ALL, E2A-PBX1, BCR-ABL, TEL-AML1, MLL rearrangement, and hyperdiploid Ͼ50 chromosomes. In addition, another ALL subgroup was identified based on its unique expression profile. Examination of the genes comprising the expression signatures provided important insights into the biology of these leukemia subgroups. Further, within some genetic subgroups, expression profiles identified those patients that would eventually fail therapy. Thus, the single platform of expression profiling should enhance the accurate risk stratification of pediatric ALL patients.
Introduction
approach was developed following the realization that pediatric ALL is a heterogeneous disease consisting of various leukemia subtypes that differ markedly in their response to chemotherapy Pediatric acute lymphoblastic leukemia is one of the great success stories of modern cancer therapy, with contemporary treat- (Pui and Evans, 1998) . By tailoring the intensity of treatment to a patient's relative risk of relapse, patients are neither underment protocols achieving overall long-term event-free survival rates approaching 80% (Schrappe et al., 2000; treated or overtreated and are thus afforded the highest chance for a cure. 2001; Pui and Evans, 1998) . This success has been achieved, in part, by using risk-adapted therapy that involves tailoring the Critical to the success of this approach has been the accurate assignment of individual patients to specific risk groups. intensity of treatment to each patient's risk of relapse. This Although risk assignment is influenced by a variety of clinical probe sets in 327 leukemia samples; greater than 4 ϫ 10 6 data elements), we used an unsupervised two-dimensional hierarchiand laboratory parameters, the genetic alterations that underlie the pathogenesis of individual leukemia subtypes figure promical clustering algorithm to group genes on the basis of similarity in their pattern of expression over the samples. The same clusnently in most classification schemes (Silverman et al., 2001; Pui and Evans, 1998) . Through systematic immunophenotyping tering method was also used to group the leukemia samples on the basis of similarities in their pattern of genes expressed and cytogenetic analysis and the subsequent molecular cloning of the genes targeted by the identified chromosomal re-(see Supplemental Data at http://www.stjuderesearch.org/data/ ALL1). Remarkably, this analysis clearly identified six major leuarrangements, a number of genetically distinct leukemia subtypes have been defined. These include B lineage leukemias kemia subtypes that corresponded to T-ALL, hyperdiploid with Ͼ50 chromosomes, BCR-ABL, E2A-PBX1, TEL-AML1, and that contain t(9;22)[BCR-ABL], t(1;19)[E2A-PBX1], t(12;21) , rearrangements in the MLL gene on chromosome 11, MLL gene rearrangement. Moreover, within the heterogeneous collection of leukemias that were not assigned to one of these band q23, or a hyperdiploid karyotype (i.e., Ͼ50 chromosomes), and T lineage leukemias (T-ALL; Silverman et al., 2001; subtypes, a subgroup of 14 cases was identified that had a distinct gene expression profile. These cases had normal, Evans, 1998). The underlying genetic lesions in these leukemia subtypes influence the response to cytotoxic drugs. For exampseudodiploid, or hyperdiploid karyotypes and lacked any consistent cytogenetic abnormality. The separation of the seven ple, leukemias that express the E2A-PBX1 fusion protein respond poorly to conventional antimetabolite-based treatment leukemia subgroups was also seen using the multidimensional scaling procedure of discriminant analysis with variance (DAV), but have cure rates approaching 80% when treated with more intensive therapies (Raimondi et al., 1990; Hunger, 1996) . Similarly, in which the data are reduced into component dimensions consisting of linear combinations of discriminating genes (Figure BCR-ABL-expressing ALLs or infants with MLL rearrangements have exceedingly poor cure rates with conventional chemother-1A). For example, using the three component dimensions that accounted for 72.8% of the variance of gene expression among apy, and allogeneic hematopoietic stem cell transplantation with an HLA-matched sibling donor has recently been shown to the subgroups, we were able to separate T-ALL (43 cases), E2A-PBX1 (27 cases), TEL-AML1 (79 cases), and hyperdiploid Ͼ50 (64 improve outcome for patients with the former leukemia subtype (Pui et al., 1991; Heerema et al., 1999; Arico et al., 2000; Biondi cases ) from the remaining ALL subtypes (114 cases). Similarly, using three different components that account for an additional et al., 2000) .
Unfortunately, the accurate assignment of patients to spe-16.1% of the variance in gene expression, we could discriminate cases with BCR-ABL (15 cases), MLL gene rearrangement (20 cific risk groups is a difficult and expensive process, requiring intensive laboratory studies including immunophenotyping, cycases), and the novel subgroup of ALL (14 cases). We next used statistical methods to identify those genes togenetics, and molecular diagnostics (Pui and Evans, 1998; Pui et al., 2001) . Moreover, these diagnostic approaches require that best define the individual groups. The expression profiles obtained using the top 40 genes per subgroup selected by a the collective expertise of a number of professionals, and although this expertise is available at most major medical centers, chi-square metric are illustrated in Figure 1B , using the twodimensional hierarchical clustering algorithm. The chi-square it is generally unavailable in developing countries. With the recent development of DNA microarrays, it is now possible to metric is a statistical test of association and provides a rankordered list of genes for each genetic subgroup. In this figure, take a genome-wide approach to leukemia classification (Perou et al., 1999; Golub et al., 1999; Alizadeh et al., 2000) . To detereach column corresponds to a single leukemia sample and each row represents the expression level of a single gene across the mine whether the single platform of gene expression profiling of leukemic blasts could replace conventional laboratory apsample set. The expression level of each gene relative to the mean expression level across all samples is represented by a proaches while simultaneously enhancing prognostic criteria, we utilized oligonucleotide microarrays to analyze the exprescolor, with red representing expression above the mean and green representing expression below the mean, and the intension of over 12,600 genes in diagnostic leukemic blasts from 360 pediatric ALL patients. These studies demonstrate that exsity of the color corresponds to the magnitude of the deviation from the mean. As shown, distinct groups of genes distinguish pression profiling is not only a robust approach for the accurate identification of known lineage and molecular subtypes of ALL, cases defined by E2A-PBX1, MLL, T-ALL, hyperdiploid Ͼ50, BCR-ABL, the novel subgroup, and TEL-AML1. In addition to but also provides new insights into their underlying biology. In addition, gene expression profiling allows the accurate identifithese specific subgroups, 65 cases (20% of the total) were identified that did not cluster into any of the leukemia subtypes. cation of some patients who are at a high risk for failing conventional therapeutic approaches.
The expression profiles of these latter cases varied markedly, suggesting that they represent a heterogeneous group of leukemias. Nearly identical results were obtained when the hierarchiResults cal clustering was performed with genes selected by other statistical metrics (see Supplemental Figures S14-S18 at http:// Expression profiling of pediatric ALL-Biologic insights To determine if gene expression profiling of leukemic cells could www.stjuderesearch.org/data/ALL1). For T-ALL, two gene clusters were identified, one expressed identify known biologic ALL subgroups, we analyzed 327 diagnostic bone marrow (BM) samples with Affymetrix oligonucleoat high levels and one at low levels, that discriminated this subtype from B lineage cases. By contrast, for each of the tide microarrays containing 12,600 probe sets. The distribution of the individual prognostic subgroups within this data set is other leukemia subtypes, the top-ranked discriminating genes primarily consisted of genes that were overexpressed within the detailed in the Supplemental Data at http://www.stjuderesearch. org/data/ALL1. specific leukemia subtype. It is important to emphasize that, with the exception of T-ALL, the identified expression profiles In an initial analysis of the gene expression data set (12,600 A: Multidimensional scaling plot using DAV of the gene expression data from 327 diagnostic BM samples generated using the 10,991 probe sets that passed the variance filter. Each case is represented by a sphere and is color-coded to indicate the specific genetic subgroup to which it belongs. Cases are displayed in gene space with each component dimension consisting of a linear combination of genes that showed the greatest variance across the data set. In the panel on the left, the space represents expression values of discriminant genes that correspond to 72.8% of the variance across the dataset, whereas the panel on the right corresponds to three separate components that represents 16.1% of the total variance. B: Hierarchical clustering of 327 diagnostic ALL samples (columns) versus 271 genes (rows). The genes used in this analysis are the top 40 genes chosen by a chi-square statistic that are most highly correlated with the seven specific class distinctions. Nine genes were identified as useful in discriminating more than one class, but each is used only once in this analysis. The normalized expression value for each gene is indicated by a color, with red representing high expression and green representing low expression, with the scale shown at the lower left.
do not represent a specific differentiation stage of the leukemic PBX1 genetic lesion and not the pre-B immunophenotype. Moreover, we were unable to define expression profiles that blasts. For example, although E2A-PBX1 is almost exclusively found in ALLs with a pre-B cell immunophenotype (Hunger, were specific for the immunophenotypically defined differentiation stages of the B lineage ALLs, including early pre-B, transi-1996), the identified expression profile was specific for the E2A- tional pre-B, and pre-B (see Supplemental Data, Tables S19-
The majority of the leukemia subtype-specific genes identified through this study were not previously known to have a S21 and Figure S20 at http://www.stjuderesearch.org/data/ ALL1). Rather, the gene expression profiles of the specific gerestricted pattern of expression ( Figure 3 ; the list of genes selected by each metric are provided in the Supplemental Data netic subgroups always predominated.
To confirm that the microarray analysis provided an accurate at http://www.stjuderesearch.org/data/ALL1). Besides having the potential to be used as new diagnostic and subclassification reflection of gene expression levels, we compared the microarray data with results for RNA levels obtained by real-time RTmarkers, these genes provide unique insights into the underlying biology of the different leukemia subtypes. For example, E2A-PCR (five genes) and with the corresponding protein levels as assessed by immunophenotype analysis performed by flow cy-PBX1 leukemias were characterized by high expression of the C-MER receptor tyrosine kinase (MERTK), a known transforming tometry (nine specific cell surface antigens). As shown in the Supplemental Data (Figures S7-S12 and Tables S4-S9 at http:// gene (Graham et al., 1994; Georgescu et al., 1999) , suggesting that C-MER may be involved in the abnormal growth of these www.stjuderesearch.org/data/ALL1), a very high degree of correlation was observed between the levels of RNA expression cells. Similarly, HOXA9 and MEIS1 were exclusively expressed in cases having MLL rearrangements, indicating that they may detected by quantitative RT-PCR and microarray analysis. Similarly, in agreement with results from immunophenotying, T linbe directly involved in MLL-mediated alterations in the growth of the leukemic cells. Interestingly, high expression of MTG16, eage-restricted RNA expression was observed for CD2, CD3, and CD8, whereas B lineage-restricted expression was oba homolog of ETO (Gamou et al., 1998) , was found in TEL-AML1 cases. Alteration of ETO family members in both t(8;21) served for CD19 and CD22 ( Figure 2A and Supplemental Data, Figure S13 ). In addition, the level of CD10 RNA expression acute myeloid leukemia (by translocation) and TEL-AML1 (by altered expression) suggests that alteration in closely correlated with protein levels, with high expression detected in TEL-AML1 leukemias, intermediate levels in E2A-the biologic function of ETO genes may be mechanistically involved in these leukemias. PBX1, and low to undetectable expression in cases with rearrangements of MLL ( Figure 2B ). Thus, microarray analysis
Little is known about the underlying molecular pathogenesis of hyperdiploid ALL Ͼ50 chromosomes, which clinically is disprovides an accurate reflection of expression levels for most genes and can be used to accurately detect the expression tinct from hyperdiploid cases having 47-50 chromosomes. This distinction is supported by the marked differences in gene exof the more common surface antigens used in the diagnostic evaluation of pediatric ALL patients.
pression profiles between these two subgroups. Although hyperdiploid Ͼ50 ALLs have an excellent prognosis, the specific velop an expression-based leukemia classification. Through a reiterative process of error minimization, these supervised learngenetic lesions responsible for the aberrant proliferation in these cases remains poorly understood. Interestingly, almost 70% of ing algorithms learn to recognize the optimal gene expression patterns for a specific subtype. Classification was approached the genes that defined this subgroup were localized to either chromosome X or 21. Moreover, the class-defining genes on using a decision tree format, in which the first decision was T-ALL versus B lineage (non-T-ALL) and then within the B linchromosome X were overexpressed in the hyperdiploid Ͼ50 chromosomes ALLs irrespective of whether the leukemic blasts eage subset, cases were sequentially classified into the known risk groups characterized by the presence of E2A-PBX1, TELhad a trisomy of this chromosome (data not shown). Detailed analysis will be required to determine the specific signaling AML1, BCR-ABL, MLL chimeric genes, and lastly hyperdiploid with Ͼ50 chromosomes. Cases not assigned to one of these pathways that are disrupted as a result of the altered expression of these genes. Lastly, the novel subgroup of ALL was defined classes were left unassigned (see Supplemental Data, Figure  S19 at http://www.stjuderesearch.org/data/ALL1). Classificaby high expression of a group of genes, including the receptor phosphatase PTPRM and LHFPL2, a gene that is a part of the tion was performed using the supervised learning algorithm, support vector machine (SVM), with a set of discriminating LHFP-like gene family-the founding member of which was identified as the target of a lipoma-associated chromosomal genes selected by a correlation-based feature selection (CFS) or, if this method selected Ͼ20 genes for a particular class, translocation (Petit et al., 1999) . Whether the LHFPL2 gene is altered by a chromosomal rearrangement in these leukemias using the top 20 ranked genes selected by a chi-square metric or one of the other metrics detailed in the Supplemental Data. remains to be determined.
As shown in Table 1 , this approach resulted in exceptionally accurate class prediction in a randomly selected training set Expression profiling as a diagnostic tool A major goal of this study was to determine if the single platform that consisted of two-thirds of the total cases (215 cases). When this classification model was then applied to a blinded test set of expression profiling could accurately identify the known prognostically important leukemia subtypes. We formally tested this consisting of the remaining 112 samples, an overall accuracy of 96% was achieved for class assignment (Table 1 and Suppleissue by using computer-assisted learning algorithms to de- mental Data, Tables S16-S18). The number of genes required pediatric ALL. Despite our success in identifying distinct leukemia subtypes that have either a very high or low risk of treatment for optimal class assignment varied between classes. A single gene was sufficient to give 100% accuracy for both T-ALL failure, risk assignment remains an imprecise process. To determine if expression profiling might further enhance our ability to (CD3D) and E2A-PBX1 (PBX1), whereas 7-20 genes were required for prediction of the other classes. Only slight differences identify those patients who are likely to relapse, we compared the expression profiles of four groups of leukemic samples: were observed in the prediction accuracies of individual classes when the process was repeated using genes selected by a
(1) diagnostic samples of patients that develop hematological relapses (n ϭ 32); (2) diagnostic samples from patients who number of other metrics, including T statistics, a novel metric referred to as Wilkins', or genes selected by a combination of remained in continuous complete remission (CCR) (n ϭ 201); (3) diagnostic samples from patients who develop therapy-induced self-organizing maps (SOM) and DAV (see Supplemental Data, Tables S13-S15). Moreover, nearly identical results were ob-AML (n ϭ 16); and (4) leukemic samples collected at the time of ALL relapse (n ϭ 25). Using DAV, distinct gene expression tained when the various sets of selected genes were used in a number of different supervised learning algorithms, including profiles were identified for each of these groups (Figure 4 ). To further assess the predictive power of the different gene -nearest neighbor (-NN), artificial neural network (ANN), and prediction by collective likelihood of emerging patterns (PCL) expression profiles, we again used supervised learning algorithms. Because of the overwhelming differences in the expres-(see Supplemental Data, Tables S16-S18). Importantly, the rare cases that were misclassified by gene sion profiles of the different leukemia subtypes, we were unable to identify a single expression signature that would predict reexpression analysis were highly informative. For example, four cases were apparently misclassified as TEL-AML1 by gene exlapse irrespective of the genetic subtype. However, within individual leukemic subtypes, distinct expression profiles could be pression analysis since they lacked a detectable chimeric transcript by RT-PCR. However, on further analysis, one case was defined that predicted relapse. Class assignment was performed using a SVM supervised learning algorithm with discrimishown by FISH analysis to have a TEL-AML1 fusion, presumably a variant rearrangement that could not be detected with the nating genes selected by CFS or, if this method returned Ͼ20 genes, we used the top 20 genes selected by T statistics (Supamplification primers used for the TEL-AML1 RT-PCR assay (see Supplemental Figure S21 at http://www.stjuderesearch.
plemental Tables S22-S24 at http://www.stjuderesearch.org/ data/ALL1). As shown, for both the T-ALL and hyperdiploid Ͼ50 org/data/ALL1). In the other three cases, reexamination of the karyotypes revealed translocations involving the p arm of chrosubgroups, expression profiles identified those cases that went on to relapse with an accuracy of 97% and 100%, respectively, mosome 12 in each case. By FISH analysis, two of these cases had deletion of one TEL allele, whereas the remaining case had by crossvalidation. Moreover, these prediction accuracies were statistically significant when compared to results from an analya partial deletion of one TEL allele (see Supplemental Data, Figure S21 ). Thus, the identified expression profiles appear to sis of 1000 random permutations of the specific patient data set ( Figure 5A and Supplemental Data). Similarly, expression reflect an abnormality of the TEL transcription factor and may provide a more accurate means of identifying a specific leukemia profiles predictive of relapse were identified for TEL-AML, MLL, or cases that lacked any of the known genetic risk features subtype defined by its underlying biology. Collectively, these data suggest that the single platform of gene expression profil-(Supplemental Data, Table S25 ). However, although the predictive accuracies of these latter expression profiles were very ing can accurately identify the known prognostic subtypes of ALL.
high by crossvalidation, they did not reach statistical significance when compared to results from an analysis of 1000 random permutations of the same patient data set, likely secondary Use of expression profiles to identify patients at high risk of treatment failure to the limited number of cases. The expression signatures predictive of relapse for T-ALL and hyperdiploid Ͼ50 ALLs are Relapse and the development of therapy-induced acute myeloid leukemia (AML) are the major causes of treatment failure in shown in Figures 5B and 5C . A key point is that no single gene overexpression of these genes is mechanistically involved in the increased risk of therapy-induced AML or is only a chance association remains to be determined. Formal proof of the predictive value of this identified expression signature will require confirmation in an independent group of patients.
Discussion
Contemporary approaches to the diagnosis of pediatric ALL requires an extensive range of procedures including morphology, immunophenotyping, cytogenetics, and molecular diagnostics. Using gene expression profiling, we now demonstrate that the single platform of microarray expression analysis can accurately identify each of the known prognostically and therapeutically relevant subgroups of childhood ALL. Distinct gene expression profiles were identified for ALL blasts with T lineage, hyperdiploid Ͼ50 chromosomes, BCR-ABL, E2A-PBX1, TEL-AML1, and MLL gene rearrangement. In addition, using a variety of computer-assisted supervised learning algorithms, overall diagnostic accuracies of 96% were achieved. This level of accuracy exceeds that typically achieved using contemporary diagnostic approaches in most medical centers. Moreover, the as- ric message by RT-PCR. As noted, each of these cases was approaches. Whether gene expression profiling will become a practical diagnostic alternative remains to be determined. It is important to stress, however, that once a diagnostic algorithm using a defined set of genes is established, its routine use in a can be used to predict the risk of relapse. Rather, patterns clinical setting will require only minimal expertise. As the cost of expression for a combination of genes were found to be of gene expression profiling decreases, this type of analysis predictive. Since few known risk-stratifying biologic features will likely become highly competitive when compared to the have been previously identified for either T-ALL or hyperdiploid cumulative cost of the various diagnostic studies that are pres-Ͼ50 ALL, our results suggest that the identified expression ently used. profiles provide independent risk-stratifying information.
One of the most surprising observations from this study A provocative observation was the identification of a distinct was the remarkable difference in the expression profiles of the expression profile in the ALL blasts from those patients who individual leukemia subtypes. Despite having relatively homogedeveloped therapy-induced AML. Because secondary AML is nous morphology and limited variability in the extent of T or B cell thought to arise from a hematopoietic stem cell that is distinct differentiation, each leukemia subtype had a distinct expression from that giving rise to the primary leukemia ( Figure 6A ), it is profile that involved a large number of genes. These observadifficult to understand how the biology of the original ALL blasts tions are in agreement with a more limited study in which the could predict the risk of developing a therapy-induced compliexpression profiles of ALLs with MLL rearrangements were cation. Nevertheless, we formally evaluated the accuracy of shown to differ from those of other acute leukemias (Armstrong expression profiling in identifying these patients. Again, no sinet al., 2001) . Remarkably, the expression differences between individual ALL subtypes were more robust than expression difgle expression profile was identified that worked across the different leukemia subgroups. However, within the TEL-AML1 ferences between either lung adenocarcinoma (Su et al., 2001) or melanoma (Ramaswamy et al., 2001 ) and bladder transitional subgroup, a distinct expression signature consisting of 20 genes was defined that identified, with 100% accuracy in crossvalidacarcinoma, tumors that conceptually would be considered more divergent. Thus, our data supports the interpretation that these tion, all patients who developed secondary AML, with a p value of 0.031 as assessed by comparison to results from an analysis leukemic subtypes are distinct biological and clinical entities. For subgroups defined by either translocation-encoded chimeof 1000 random permutations of the patient data set ( Figure  6B ). Genes within this signature included RSU1, a suppressor ric transcription factors or altered signaling proteins such as BCR-ABL, the presence of a distinct gene expression profile is of the RAS signaling pathway, and MSH3, a mismatch repair enzyme ( Figure 6C and Supplemental Data, Tables S26 and not completely unexpected. By contrast, the identification of a unique expression profile for novel ALL cases with Ͼ50 chromo-S27 at http://www.stjuderesearch.org/data/ALL1). Whether the A: Genes predictive of the class distinction relapse versus continuous complete remission (CCR) for either T-ALL or hyperdiploid Ͼ50 ALL (HD) were chosen by CFS or T statistics. The selected genes were then used in a SVM supervised learning algorithm, and performance was assessed by a crossvalidation experiment. The apparent accuracies of prediction are indicated. The significance of the prediction accuracy was determined by performing 1000 permutation experiments for each subtype-specific group (see Supplemental Data at http://www.stjuderesearch.org/data/ALL1). The percentage of these 1000 random partitions that gave a prediction accuracy equal to or better than that for the relapse prediction was taken as a p value. B and C: The expression pattern of the 7 and 20 genes that were selected as discriminators of relapse versus CCR in T-ALL and HD cases, respectively. The GenBank accession number and the gene symbol or DNA sequence name are listed on the right side of each panel.
somes is surprising. Examination of the expression profiles of ultimately converge on these critical functions. Clearly, some of the identified expression differences result from variations hyperdiploid Ͼ50 and the ALL subgroup identified here should provide important new insights into the underlying pathogenesis in lineage or stage of differentiation. What proportion of the remaining expression changes are mechanistically involved in of these leukemic subtypes. The expression profiles of these and the other leukemia subtypes has not only provided insights transformation remains to be determined. Similarly, determining how the identified expression differences are involved in the into their biology but has also resulted in the identification of a number of genes that should prove useful as markers to monitor unique clinical biology of the leukemias, including their distinctive responses to particular types of chemotherapy, remains to patients for minimal residual disease. In addition, some of the identified genes, such as the C-MER receptor tyrosine kinase be defined. One of the most promising aspects of gene expression proin E2A-PBX1, may prove to be useful targets against which novel therapeutic agents could be developed.
filing is the hope that it will improve the ability to accurately identify those patients who are at a high risk of failing convenThe marked differences seen in the expression profiles of the various ALL subtypes suggest that transformation may occur tional therapy. Strikingly, our results demonstrate that the gene expression profiles differ between the diagnostic samples of through distinct pathways. Although only a limited number of growth control mechanisms need to be subverted to result in patients who relapse and those who remain in continuous complete remission. Moreover, specific expression profiles in the cellular transformation (Hanahan and Weinberg, 2000) , our data suggest that in pediatric ALL, multiple pathways may exist and diagnostic samples of either T-ALL or hyperdiploid ALL appear A: Schematic illustration showing that therapy-induced AML (2 nd AML) is believed to arise from a hematopoietic progenitor that is distinct from the one that gave rise to the original ALL leukemic clone. B: Genes within the diagnostic ALL BM samples that were predictive of development of therapy-induced AML were selected by their MIT score and then used in a SVM supervised learning algorithm. Performance was assessed by a crossvalidation experiment, and the results are indicated as apparent accuracy. The significance of the prediction accuracy was determined by performing 1000 random permutation experiments, with the p value indicating the percentage of these random experiments that gave a prediction accuracy equal to or better than the secondary AML prediction. C: The expression profile of a subset of the genes selected as predictors of the development of secondary AML in TEL-AML1-positive ALLs. The GenBank accession number and the gene symbol or DNA sequence name are listed on the right of the panel.
to be accurate predictors of relapse. Although these data will within the human genome (Hogenesch et al., 2001 ). In the future, the use of higher-density chips should not only further enhance need to be validated in prospective studies, these findings raise the expectation that, in the future, this type of analysis will be our ability to accurately identify those patients who will relapse, but should also provide a clearer view of the underlying biology. used to make therapeutic decisions. In addition, the identified expression profiles should provide critical insights into the unThe provocative finding of an expression profile in the diagnostic samples that identifies patients who subsequently develderlying mechanisms that contribute to relapse. The observation that we could not identify a common expression profile that oped therapy-induced AML will need to be validated in an independent cohort of patients. Although a distinct expression predicted relapse irrespective of the genetic subtype suggests that a unifying mechanism of relapse may not exist. Rather, profile was defined that identified those TEL-AML1 ALL patients who developed secondary AML, it remains to be determined if mechanisms of relapse or drug resistance may differ among leukemia subtypes. Alternatively, the identified expression prothe profile represents genes that are mechanistically involved in the enhanced risk or are only statistical associations. Reasfiles may consist of genes that are chance associations with pending relapse and not genes directly involved in the underlysessment of these samples using higher-density chips will allow a significantly broader view of the genes that characterize the ing biology. It is important to keep in mind that the present analysis falls far short of a total transcriptional profile of the ALL blasts of patients who develop secondary AML and may thereby help to answer this question. Despite these caveats, leukemic blasts. Although 12,600 probe sets are present on the microarray, the total number of genes that this represents these findings suggest the concept that expression profiling of leukemic blasts, and possibly nonmalignant hematopoietic accounts for less than 20% of the estimated number of genes Palo Alto, CA). cDNA was synthesized using a T-7 linked oligo-dT primer, cells, may enhance our ability to identify patients who are at a and cRNA was then synthesized with biotinylated UTP and CTP. strong et al., 2001; Ferrando et al., 2002) . Although there is across the sample set, and minimum quality control standards were estaba high degree of correlation between our results and those lished for including a sample's hybridization data in the study (see Supple- presented in these other studies, subtle differences are evident.
mental Data at http://www.stjuderesearch.org/data/ALL1). To ensure consisForemost is the observation that not all MLL discriminating tency of data acquisition throughout the study, 10% of samples were run genes identified in the Armstrong paper were found to distinin duplicate. An exceedingly high reproducibility was observed between guish this ALL subtype in our analysis. Using a much larger replicate samples, with less than 1% of genes having a variation in average intensity difference (AID) of Ͼ2-fold. The primary hybridization data are availnumber of cases, we find that some of the genes that were able at our website (http://www.stjuderesearch.org/ALL1).
originally found to correlate with MLL in fact have a broader expression pattern than was originally appreciated. Similarly, in
Statistical analysis
T-ALL, by using a much larger number of genes to assess the Unsupervised hierarchical clustering, principal component analysis (PCA), expression profiles, we now find prognostic markers that were discriminant analysis with variance (DAV), and self-organizing maps (SOM) not identified in the study of Ferrando.
were performed using GeneMaths software (v.1.5, Applied Maths, Belgium). Data reduction to define the genes most useful in class distinction was In summary, contemporary risk stratification requires a comperformed using a variety of metrics as detailed in the Supplemental Data bination of methodologies and fails to identify many patients at http://www.stjuderesearch.org/data/ALL1. Genes selected by the various who are at high risk of drug-induced toxicities. The data premetrics were used in supervised learning algorithms to build classifiers that sented here suggest that the single platform of gene expression could identify the specific genetic or prognostic subgroups. Algorithms used profiling provides a robust and accurate approach for the diag- for studies of pediatric leukemia.
